New Trial Recruiting Primary, Post-PV, and Post-ET Myelofibrosis Patients

Official Title: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib 

CTI Biopharma is recruiting patients for the PACIFCA trial, a randomized phase 3 study evaluating Pacritinib in patients with myelofibrosis and less than 50,0000 platelet count who have never received a JAK2 inhibitor or who have had no more than 90 days of prior JAK2 inhibitor exposure.

Click here for more information.

Receive updates on the latest MPN news & events.

Find out ways you can help support MPN patients and researchers.



Get free, timely information on living with an MPN.